Skip to main content

Mark Allen, Daniel Von Hoff, Raymond Woosley, Ernst Mayr, Scott Garrett, and John Reed

Premium

Tripos Discovery Research has promoted Mark Allen to senior vice president and managing director. Allen succeeds Peter Hecht, who will become CEO of Oridis Biomed, but will remain a Tripos scientific advisor. Allen was previously head of drug discovery support for Novartis Pharma UK, where he was head of drug discovery support. Prior to that position, Allen worked at CIBA-Geigy Pharma UK, and was eventually appointed head of core drug technologies. Following the formation of Novartis in 1997, he was named Head of Drug Discovery Support for Novartis Pharma UK.


HTG appointed Daniel Von Hoff and Raymond Woosley to its scientific advisory board. Von Hoff is the past president of the American Association for Cancer Research, a fellow of the American College of Physicians, and a founder of ILEX Oncology, which was recently acquired by Genzyme. Woosley recently became president of the Critical Path Institute, and is currently vice president for health sciences at the University of Arizona, and dean of the university’s College of Medicine.


Influential evolutionary biologist Ernst Mayr is dead at 100 years old. Mayr worked as curator of the American Museum of Natural History in New York in the 1930s and 1940s, and later joined Harvard’s Faculty of Arts and Sciences in 1953 as Alexander Agassiz Professor of Zoology and led Harvard’s Museum of Comparative Zoology from 1961 to 1970, retiring in 1975. Mayr was a major force in securing evolutionary biology’s central role in the science. Born July 5, 1904, in Kempten, Germany, Mayr earned a medical degree from the University of Greifswald in 1925, earning a PhD 16 months later. He was the recipient of the National Medal of Science in 1970, the Balzan Prize in 1983, the International Prize for Biology in 1994, and the Crafoord Prize in 1999.


Scott Garrett will become CEO of Beckman Coulter on Feb. 21, the company said last month. He succeeds John Wareham, who is retiring. Wareham will continue as chairman of the board until April 7. Garrett joined Beckman’s board of directors on Jan. 17. He has been Beckman’s president and chief operating officer since the end of 2003 and joined the company in 2002. Prior to that, he was CEO of Garrett Capital Advisors and CEO of Kendro Laboratory Products.


John Reed, Burnham Institute president and CEO, has been named as a director of California’s stem cell program.

Filed under

The Scan

UK Funds to Stay Ahead of Variants

The UK has announced a further £29.3 million to stay on top of SARS-CoV-2 variants, the Guardian reports.

Push for Access

In a letter, researchers in India seek easier access to COVID-19 data, Science reports.

Not as Cold

Late-stage trial results are expected soon for an RNA-based vaccine that could help meet global demand as it does not require very cold storage, the New York Times writes.

Genome Research Papers on Microbes' Effects on Host Transfer RNA, Honeybee Evolution, Single-Cell Histones

In Genome Research this week: influence of microbes on transfer RNA patterns, evolutionary relationships of honeybees, and more.